Evaluation of a developmental hierarchy for breast cancer cells to assess risk-based patient selection for targeted treatment

Sarah A. Bliss¹,², Sunirmal Paul¹, Piotr W. Pobiarzyn¹,², Seda Ayer³, Garima Sinha¹,², Saumya Pant³, Holly Hilton⁴, Neha Sharma³, Maria F. Cunha¹, Daniel J. Engelberth¹,², Steven J. Greco¹, Margarette Bryan⁵, Magdalena J. Kucia⁵, Sham S. Kakar⁵, Mariusz Z. Ratajczak⁵ & Pranela Rameshwar¹,²

This study proposes that a novel developmental hierarchy of breast cancer (BC) cells (BCCs) could predict treatment response and outcome. The continued challenge to treat BC requires stratification of BCCs into distinct subsets. This would provide insights on how BCCs evade treatment and adapt dormancy for decades. We selected three subsets, based on the relative expression of octamer-binding transcription factor 4 A (Oct4A) and then analysed each with Affymetrix gene chip. Oct4A is a stem cell gene and would separate subsets based on maturation. Data analyses and gene validation identified three membrane proteins, TMEM98, GPR64 and FAT4. BCCs from cell lines and blood from BC patients were analysed for these three membrane proteins by flow cytometry, along with known markers of cancer stem cells (CSCs), CD44, CD24 and Oct4, aldehyde dehydrogenase 1 (ALDH1) activity and telomere length. A novel working hierarchy of BCCs was established with the most immature subset as CSCs. This group was further subdivided into long- and short-term CSCs. Analyses of 20 post-treatment blood indicated that circulating CSCs and early BC progenitors may be associated with recurrence or early death. These results suggest that the novel hierarchy may predict treatment response and prognosis.

Despite improved treatments, breast cancer (BC) remains a clinical problem. BC cells (BCCs) can remain dormant for decades, commonly referred as cellular dormancy. Cellular dormancy is a method by which the BCCs enter a state of cellular quiescence until it receives a cue from the environment to proliferate. Clinical outcome studies have documented disease re-occurrence from 1–20 years after initial treatment regardless of lymph node involvement. There could be a long lag time between the initiation of the tumor to clinical diagnosis. During this lag time, metastatic BCCs could escape into the circulation from undetectable, but developing tumor. The bone marrow (BM) can facilitate the survival of dormant BCCs for decades. Thus, the BM is a significant organ when considering treatment for BC. Approximately 30% of BC patients have BM metastasis and about 50% of those may have cancer recurrence. There is a strong correlation between BCCs in the BM and relapse. However, a direct evidence on cause-effect relationship between BCCs in the BM and metastatic recurrence requires additional studies. Regardless, it is evident that the presence of BCCs in the BM may be prognostic. Thus, studies of BCCs using a developmental hierarchy as part of the characterization should be considered in future studies to correlate any association between developmental phenotype and outcome events including response. The stratification of BCCs into a robust hierarchy is missing in the literature. This study has begun to address this problem using gene chip arrays.

¹Rutgers New Jersey Medical School, Newark, NJ, USA. ²Rutgers School of Graduate Studies at New Jersey Medical School, Newark, NJ, USA. ³Biocon Bristol Myers Squibb R&D Center, Bangalore, India. ⁴PPD Laboratories, Wilmington, NC, USA. ⁵University of Louisville, Louisville, KY, USA. Sarah A. Bliss, Sunirmal Paul, Piotr W. Pobiarzyn and Seda Ayer contributed equally to this work. Correspondence and requests for materials should be addressed to P.R. (email: rameshwa@njms.rutgers.edu)
Metastasis can occur with < 0.1% of the BCCs entering the blood\(^1\). This percentage of BCCs that is linked to metastasis is similar to the frequency of cancer stem cells (CSCs) in tumor cell lines\(^2\). Since BCCs are heterogeneous, predicting which subset of BCCs will metastasize is difficult and hinders identification and stratification of BCCs hierarchically. Stratification would provide insight on the tissue microenvironment (TME) and how the TME influences drug resistance to therapy and immune responses\(^{20,21}\). A hierarchical stratification of BCCs could allow for precise targeting of BCCs in organs such as the BM. Presently, the BM poses a major challenge to acquire effective treatment to target BCCs that require targeting the milieu of immune suppressor cells such as mesenchymal stem cells in the BM\(^3,4,22\). Treatment will need to overcome the ability of endogenous BM cells to sustain quiescence of BCCs\(^3,4,23–29\). Specifically, cells of the BM niche can retain BCCs in a dormant phase, making them difficult to treat. In addition, it is important to note that any treatment of BCCs within the BM microenvironment must avoid overt toxicity to the endogenous hematopoietic stem cells\(^{27,30,31}\).

There is a growing acceptance among the scientific community that new treatments are needed to target CSCs since this will remove the initiating cells and halt the propagation of the tumor\(^{32–34}\). The premise underlying this strategy is that the loss of the initiating tumor cells will cause the bulk cancer to regress. However, this strategy needs to consider the possibility that the non-CSCs/cancer progenitors may dedifferentiate into CSCs\(^{31,35,36}\). We address these problems by developing a hierarchy of BCCs since this would be needed to study if dedifferentiation occurs, and if so, identify the ease by which the particular BCC subset can dedifferentiate. We identified three new membrane proteins, GPR64, TMEM98, FAT4 using the Affymetrix data analyses\(^{37,38}\). These membrane proteins, along with other markers reported for CSCs, were used to establish a hierarchy of BCCs. The developed hierarchy was tested with blood samples from BC patients that were obtained after treatment. The circulating BCCs were then associated with the patients’ outcome up to two years after treatment.

**Results**

**Affymetrix Gene Array Analyses/Differential Expression.** As the first step to stratify BCCs, we performed global gene expression analyses using MDA-MB-231. The method used to select three different subsets was previously described\(^3\), and based on the relative GFP intensities of cells stably transfected with the Oct4A promoter linked to GFP. Based on previous studies, we showed a direct correlation between Oct4A and GFP intensity\(^3\). Despite previous studies showing low levels of Oct4 protein maintaining pluripotency\(^{39}\), in our model, which is based on previous report, functional and biochemical studies indicated that the highest expression of Oct4A is linked to ‘stemness’ of BCCs\(^3\). We should also note that most of the Oct4 pseudogenes are not translated to proteins. Thus, for the purpose of simplifying our model, we have designated relative GFP intensities with Oct4A promoter as Oct4hi (5%), Oct4 med (30%) and Oct4 low (10%)\(^3,26\) (Fig. 1A). We then performed global gene expression analyses with total RNA from four different sets of MDA-MB-231, using the Affymetrix Genechip Human Genome U133 Plus 2.0 arrays. Oct4hi and Oct4low were analyzed in quadruplicates and Oct4med, in duplicate (Fig. S1). The data were analyzed with multiple database and software tools, Partek\(^R\) Genomics Suite software, Gene Spring GX 10.0.2, QIAGEN’s Ingenuity\(^R\) iReport, and BRB-Array Tools.

We conducted principal component analyses (PCA) to determine the similarities and differences among array results of each sample. The results indicated confidence with respect to similarities as indicated by clustering of the replicates from each BCC subset (Fig. 1B). Additionally, the clusters were far apart, indicating distinct separation of the overall gene expression pattern among the subsets (Fig. 1B).

BRB-Array Tools provided a multi-dimensional scaling analysis, supporting distinct gene expression among the samples and depicted the tight grouping of replicate sample and greater separation among the BCC subsets (Fig. S2). The similarities and differences were obvious in the hierarchical clustering of the samples linking Oct4med and Oct4hi (Fig. 1C). Both subsets were linked to Oct4lo BCCs, further supporting a hierarchy among the three Oct4A subsets.

Heat maps generated with Partek and BRB-Array Tools incorporated the differentially expressed genes. The map with 6,300 genes showed clustering among the replicates, but with distinct gene intensities among the three BCC subsets (Fig. 1D, left). A hierarchical clustering of genes with +1.1 fold changes (2,227 genes) showed distinct pattern of gene expression among the three subsets (Fig. 1D, right). The results showed distinct global gene expression among BC subsets.

The analyses programs could not incorporate the data for Oct4med BCCs due insufficient replicates. Thus, we compared Oct4hi and Oct4lo BCCs for differentially expressed genes using the normalized signal values. Those at higher statistical relevance are highlighted (p value, < 0.05; fold change > 2.0) (Fig. 1E, Table S1).

**Biological networks analysis/canonical pathways.** The IPA knowledge base compared genes with >1.5 fold for those associated with breast and ovarian cancers, and then determined the connections to Oct4/POU5F1 (Fig. 1F). Molecule Activity Predictor illustrates activation or inhibition of regulators/molecules in the networks. In Oct4hi BCCs, Oct4/POU5F1 expression was highly activated including its 34 transcriptional activators. Activation used in the network’s output implies functional activation and increase in the gene expression. High expression of Oct4 showed upregulation/activation of genes linked to TNFα signaling, TGFβ1, TGFβ2, INHBA, SMAD3 and SMAD4, suggesting that Oct4 may be linked to microenvironmental functions. In general, the tumor cells are within a niche of cytokines. In Oct4med BCCs, TNFα was inhibited and TGFβ signaling molecules: either downregulated (TGFβ2) or poorly activated (TGFβ1, TGFβBR2, SMAD3 and SMAD4). Interleukins (IL-1, IL-2 and IL-4) and the proinflammatory CCL2 were highly activated in SNAI1, SNAI2, TWIST1, ZEB1 BCCs. The key molecules linked to epithelial mesenchymal transition (EMT), SNAI1, SNAI2, TWIST1, ZEB1, CXCL12, VIM, CDH2, MMP2, CXC4, ERBB2, RAC1, Notch, PARD6A and PARD6G, were highly activated whereas E-cadherin (CDH1) and connexin-43 (GJA1) were inhibited. We also analyzed the data set for membrane-spanning genes, which is the focus of this paper. Our goal was to use the dataset to identify novel genes that can stratify BCCs.
Figure 1. Selection of samples for Affymetrix Genechip arrays with validation of groups. (A) A scattergram used to select different subsets from MDA-MB-231 cells, stably transfected with pEGFP1-Oct3/4 (left panel). The relative GFP intensity of the three subsets are also depicted in a histogram (right panel). (B) PCA generated from Partek analysis, showing the distribution of conditions and clustering of sample replicates. (C) Hierarchical clustering of the samples using 2227 genes differentially expressed at $p < 0.001$ and FDR < 1.12%. (D) Heat map with hierarchal clustering generated from Partek compares all three conditions and represents 6300 genes differentially expressed (1.2+/−fold) at $p < 0.1$ and 10% FDR (false discovery rate). Two-sample T-test or F-test (more than 2 classes) based $p$ value was calculated for each significant gene with random variance model. (E) Molecular interaction network of BC overrepresented genes associated with OCT4-expressing BCCs generated from the information in the Ingenuity knowledge base. Top upstream regulators, identified by IPA core analysis, were incorporated in the network. Molecule Activity Predictor (MAP) illustrates upstream/downstream activation or inhibition of molecules in the network. Solid lines represent direct relationship and dashed line represents indirect relationship between nodes. Prediction legend and gene product’s functional class are shown in the legend key. (F) A scatter plot developed in Genespring using normalized signal values in Log$_{10}$ scale. The statistical significance was assessed with an unpaired $t$-test between Oct4$^+$ and Oct4$^-$, cut-off points were $p$-value < 0.05 and fold-change > 2.0. Specific genes of interest have been annotated on the plot.
Selection of markers in the gene set. The differentially expressed genes were validated by real-time PCR. We showed the results for a few, in particular those with immediate interest since we sought membrane proteins for the stratification of BCCs; hence the selection of FAT4, TMEM98, and FN1 using whole cell extracts expression from Oct4 hi, Oct4 med and Oct4 low, isolated as for A. The results represent four different independent experiments.

**Figure 2.** Expression of selected genes in BCC subsets. (A) Real time PCR for GPR64, FAT4, TMEM98, ALOX5 AP, DUSP4, RAP1A and FN1. The RNA was isolated from Oct4 hi, Oct4 med and Oct4 low subsets from MDA-MB-231 stably transfected with pEGFP1-Oct3/4. The results are shown as relative to β-actin expression with mean ± SD for four independent experiments. (B) Western blots for GPR64, TMEM98, FAT4, RAP1A and FN1 using whole cell extracts expression from Oct4 hi, Oct4 med and Oct4 low, isolated as for 'A'. The results represent four different independent experiments.
the Oct4hi subset, which has been shown to be the CSC. In summary, the findings validated FAT4, TMEM98 and GPR64 as key membrane proteins for further development of a hierarchical rank among BCC subsets.

ALDH1 and Telomere Length in BCC subsets. CSCs have been reported to be within the Oct4hi BCC subset. Since ALDH1 has been reported in CSCs (38), we examine the different BCCs for ALDH1. Positive control with K562 cells showed a major shift to the right (Fig. 3A). MDA-MB-231 cells showed 4.25% (+) for ALDH1 (Fig. 3B). The observation was consistent with BCCs comprise of ~5% CSCs (Fig. 3B). Next, we stratified BCCs, based on the relative intensities of fluorescence in cells stably transfected with Oct4-dsRED-SB. These analyses could not use Oct4-GFP due to the overlap with the ALDH1 substrate on the FACScan. BCCs were stably transfected with pOct4-dsRED-SB. Since we used this vector for the first time, we validated its function by treating the transfectants with Bix. The purpose of using Bix is to inhibit methytransferases and deacetylation of the Oct4 regulatory region within pOct4-dsRED in all BCC subsets, regardless of endogenous expression.40. The results with Bix indicated that pOct4-dsRED was functional (Fig. 3C). Using the gating scheme in Fig. 3D, 40% ALDH1(+) was observed in Oct4hi, 9% in Oct4hi/med and no detection in the Oct4A reduced BCC subsets (Fig. 3E).

High telomerase generally correlates with increase in the telomere length. We therefore examined Oct4hi, Oct4med and Oct4lo BCCs for telomere length. The results showed a direct correlation between Oct4 levels and telomere length (Fig. 3F).

TMEM98, GPR64 and FAT4 in BCC subsets. BCCs with stable pOct4-GFP were studied for TMEM98, GPR64 or FAT4 by flow cytometry. Gating the MDA-MB-231 and T47D based on Oct4A expression (Fig. 3G), we observed similar results. Thus, representative histograms for MDA-MB-231 indicated TMEM98, GPR64 and FAT4, Oct4low > Oct4med > Oct4hi (Fig. 3H). The results indicated distinct expressions for TMEM98, FAT4 and GPR64 among the BCC subsets.

ALDH1 was detected in 40% of Oct4hi BCCs (Fig. 3E). Since this subset also contained tumor initiating cells, we proposed that Oct4hi BCCs might be heterogeneous. Thus, we analyzed Oct4hi BCCs for FAT4, TMEM98 and GPR64, based on scatter pattern. The Oct4hi BCCs (Fig. 3I, R3) were stratified by side (SSC) and forward scatter (FSC) (Fig. 3I, R4-R6) and then analyzed for FAT4, TMEM98 and GPR64. The results confirmed heterogeneity within the Oct4hi BCCs with respect to the three markers (Fig. 3I, lower panels).

Distribution of TMEM98, GPR64 and FAT4 within CD44+ /CD24− BCCs. CD44 + CD24− BCCs, which were reported to be markers of CSCs, needs further hierarchical stratification as this subset was shown to be homogeneous with respect to CSCs.3,8 We therefore studied how the CD44 + CD24− BCCs can be further stratified based on TMEM98, GPR64 and FAT4 expressions. We observed a shift to the right for each marker, indicating their expression (Fig. 4/middle panels). Next we analyzed CD44 + CD24− BCCs based on Oct4 (hi, medium, low) for TMEM98, GPR64 and FAT4. The geometric (Geo) mean for TMEM98 showed its presence on Oct4 (hi/med/lo) and, GPR64 and FAT4 on Oct4 (med/lo) CD44 + CD24− BCCs.

Assembling BCC hierarchy. The methods used for cell lines, analyses of ALDH1 used to assemble the hierarchy of BCCs are summarized in a flow diagram (Fig. S4). Although Oct4hi BCCs were shown to contain CSCs,3,8 we only found 40% ALDH1+ with 9% at Oct4hi and Oct4med interface (Oct4hi/med) (Fig. 3E). We assigned the Oct4med/med BCCs with reduced Oct4A-GFP intensity as short-term BC repopulating cells (BC-RC) and assigned Oct4hi subset with the highest GFP intensity and high telomerase as long-term BC-RC (Fig. 5). We branched Oct4hi BR-RC based on the side scatter (SSC) for FAT4, GPR64 and TMEM98 (Fig. 3J, upper left).

Oct4lo BCCs with further stratification of GFP intensities formed branches from the early BC progenitors (left 'branches') (Fig. 5, third circle). Similar analyses established Oct4lo BCCs (Fig. 5, 4th circle). Oct4med and Oct4 BCCs, based on FAT4, GPR64 and TMEM98, divided these subsets into progenitors and 'late progenitors' (Fig. 5). CD44 + /CD24− BCCs were demarcated due to varied Oct4A and FAT4, TMEM98 and GPR64 (Fig. 4) for inclusion into the hierarchy.

Identifying circulating tumor cells in BC patients. We investigated if the developed hierarchy can predict treatment response and prognosis in 20 BC patients (Table 1). Due to ethical reasons, we studied time points, mostly after treatment using blood remaining after clinical tests. Table 1 describes the demographics and disease course of the patients. Flow cytometry with markers shown in the hierarchy (Fig. 5) assigned the developmental stage of BCCs for the patients (Table 2). The method used to analyze the patients' samples were similar to analyses of cell lines as outlined in Fig. S4. Subject 5 showed high amounts of CSCs before treatment and early BC progenitors after treatment. At the time of writing (6 months post-treatment), this subject was diagnosed with bone metastasis. Similarly, subject 13 ended treatment with circulating CSCs and shortly after was diagnosed with bone pain. The preliminary studies indicated that the markers in the hierarchy may predict BC outcome and treatment response.

Discussion

We report on the genetic and phenotypic differences in BCC subsets with a working hierarchy. The population with high Oct4A showed heterogeneity depending on the scatter pattern and CD44/CD24 expression (Fig. 5). ALDH1, which is generally linked to stem cells was incorporated to demarcate the most primitive BCCs into more and less mature cells, with the possibility of varied multipotency (Fig. 5).

We applied the hierarchy (Fig. 5) by testing patients' blood during and after treatment (Tables 1 and 2). The analyses were done with limited amount of blood since the samples were those remaining after clinical diagnosis. The data indicated that the hierarchy may be relevant to treatment response and long-term outcome. The study lacked a timeline change due to the ethics of drawing blood for research when the patients were on chemotherapy.
Figure 3. Characterization of BCC subsets. ALDH1 activity was assessed in positive control with K562 cells (A) and experimentally, with heterogeneous MDA-MB-231 cells (B). The presence of Oct4-dsRED-SB in MDA-MB-231 cells was determined by Bix treatment in flow cytometry (C). Different subsets of Oct4-dsRED-SB-transfected MDA-MB-231 cells (D) were assessed for ALDH1 (E). Similar sorting of three MDA-MB-231 subsets were analyzed for telomere length using the TeloTAGG kit (F). MDA-MB-231, stably transfected with Oct4-GFP (left panel) was labeled with PE-anti-TMEM-98, -GPR64 and -FAT4 and analyzed by flow cytometry based on the relative GFP levels (n = 5; G and H). Further assessment for TMEM-98, GPR64 and FAT4 within Oct4hi BCCs was based on size. Oct-4-GFP transfected MDA-MB-231 cells were gated based on GFP expression (I, top second panel) followed by gating of the 5% of cells with the highest GFP (I, R3, top third panel-Oct4hi). R3 was divided based on side (SSC) and forward scatter (FSC) (R4-R6) and then analyzed for TMEM98, GPR64 and FAT4 (I, lower panels). The results represent four independent experiments.
Subject (#5) was assessed before and after treatment since she was not anemic and donated additional blood samples. As expected, Subject 5, who was a relapsed patient, started with high CSCs and ended with early progenitors. After 6 months, this patient was presented with bone metastasis. The information provided with the blood samples is crucial.

**Figure 4.** Co-expressions of TMEM98, GPR64, and FAT4 in the CD44+/CD24− BCC subset. BCCs, stably transfected with Oct4-GFP, were co-labeled with CD44-APC and CD24−PE and the population of CD44+/CD24− (Top panels) further studied for the expression of TMEM98, GPR64, and FAT4 (Middle panels). CD44+/CD24− populations were further stratified based on Oct4 expression (Oct4hi, Oct4med, and Oct4low) and then studied for TMEM98, GPR64, and FAT4 (Lower panels). The Δ Geometric (Geo) mean fluorescence intensity (MFI) for TMEM98, GPR64, and FAT4 are shown in each panel. The Geo mean was calculated as the change from the actual MFI – the MFI of the isotype.
samples suggested the hierarchy may aid be relevant to precise treatment for BC. Residual BCCs at the lower end of the hierarchy may predict a good outcome, perhaps due to their inability to initiate a tumor. This may contrast residual BCCs in the upper hierarchy, which could indicate poor prognosis. Also, BCCs the more primitive residual cells may dedifferentiate into CSCs.

Despite the reproducibility among the replicates in the arrays, some of the changes could not be validated by real time PCR. This may be explained by the RMA normalization method, which entails averaging the intensity of all probes. Since we were interested in selecting membrane proteins for clinical application, we focused on those genes then selected TMEM, GPR64 and FAT4, which contributed to an expanded BCC hierarchy.

CD44+ /CD24− BCCs showed varied expressions of TMEM98, GPR64 and FAT4 in subsets based on Oct4A levels (Fig. 4). These findings suggested that CD44+/CD24− BCCs while encompassing CSCs, could be heterogeneous. The identification of surface markers to stratify BCCs is important for the isolation of primary subsets thereby avoiding in vitro changes of the primary tumor. The hierarchy developed from this study can be used to select primary BCC subsets as would be required for precise analyses in cancer biology.

FN in Oct4 hi BCCs was highly significant due to its link to epithelial-mesenchymal-transition. Since the CSCs can adapt dormancy, the production of FN1 within the stromal compartment could be an indicator that the dormant BCCs have become part of the normal hematopoietic microenvironment, ensuring their survival. In BM, the dormant BCCs will need to survive within a complex system of hematopoiesis, and FN1 is part of the BM stromal microenvironment.

The established a network with the microarray data explained how Oct4 (POU5F1) was linked to the validated genes (Fig. S5). Since Oct4 expression was used to isolate the different BCC subsets, the link between Oct4 and other genes provided insights into how this stem cell-associated gene Oct4, which can demarcate different subsets, is linked to developmental stages of BCCs, and the three membrane markers, TMEM98, FAT4 and GPR64. Not a surprising link, Oct4 connected to Twist, which is gene associated with EMT. Similar links to Oct4 was shown for additional markers in Fig. 1E. The link among genes in the Oct4 hi BCCs, shown to comprise the CSC subset, is relevant to an understanding of CSC survival, and the development of targeted treatment.

Despite the lack of reliable markers of CSCs, this study has begun to show several potential markers. It is yet to determine if the newly identified markers can identify BCCs in all microenvironments, or if the markers might be involved in the behavior of the BCCs within a specific organ. 

**Figure 5.** Working hierarchy of BCCs. The hierarchy was based on the analyses of BCCs depending on Oct4A expression, previously reported. The present studies are based on the use of additional antibodies, identified in the gene chip arrays (FAT4, TMEM98 and GPR64). The studies were done in combination of known markers of CSCs: ALDH1, CD24 and CD44.
regulators of Oct4. In summary, this study has just begun to determine how the Oct4 gene is linked to gene expressions and function. Together the data can be combined for long-term outcome studies, and to sort subsets of BCCs for functional studies. The telomere length shown in this study begins to examine functional studies. We anticipate to isolate primary BCC subsets to expand on these studies, in addition to other functional analyses. The biological replicates presented in this study used one cell line. The data seem to fit the triple positive BCCs since T47D cells were used in the flow cytometry studies. The hierarchy developed from these studies were applied to patients with phenotypically different tumors, with respect to hormone receptor expression. Thus, although the limitation in the initial studies is the lack of analyses with T47D, the data provide information to expand the clinical analyses in a large cohort of patients.

This paragraph discusses the translational relevance of the study. The stratification of BC developmental subsets for clinical translational purposes is a major hurdle. The consequence being the lack of clarity to determine the cancer subsets being targeted. If the relative maturity of the surviving BCCs can be identified, this may provide insights on the patient outcome, such as time to cancer re-occurrence. We applied genomic data from Affymetrix analyses to develop a hierarchy (working) in which the least mature BCCs are placed at the top. The working hierarchy forms the basis for future studies to expand the relative maturity of BCCs. The hierarchy incorporated TMEM98, GPR64 and FAT4, CD44, CD24, ALDH1 and Oct4A. The significance of the hierarchy was evaluated by analyzing the blood of patients. Due to ethical constraints, we mostly collected blood samples after treatment to evaluate what specific cancer subset remained. The patients’ outcome was monitored up to 1–2 years after the last treatment, which coincided with the blood testing. Although 24 blood samples were collected, we could only test 20 due to technical difficulties. Despite the lack of a larger study with statistical analyses, the current data strongly suggested that the hierarchy could predict treatment response and outcome. A larger multi-center control trials could lead to the development of precise treatment for breast cancer patients.

The final paragraph discusses the limitation of the study and provide a plan for future studies. We previously performed functional assay to show that Oct4hi BCCs comprise the tumor initiating cells. The present study used phenotypic studies and apply the findings to test clinical samples from BC patients. However, the hierarchy shown in Fig. 5 requires functional studies using in vivo models. We are in the process of generating antibodies to the extracellular region of GPR64, FAT4 and TMEM98. The antibodies will be used to select subsets of BCCs from

| Patient | Age (Yrs) | Ethnicity | Diagnosis | Clinical Disease at Blood Sampling | Treatment |
|---------|-----------|-----------|-----------|-----------------------------------|-----------|
| 1       | 50        | Black     | Relapse ER+PR+Her2− | Yes | Hormone |
| 2       | 35        | Hispanic  | Relapse ER-PR-Her2− | Yes | Chemotherapy |
| 3       | 60        | Black     | Relapse ER-PR-Her2− | Yes | Chemotherapy |
| 4       | 40–49     | Caucasian | Relapse ER+PR+Her2− | Yes | Pre-Chemotherapy (Palbociclib) |
| 5A      | ↓         | ↓         | ↓         | ↓      | No Post-Chemotherapy |
| 6       | 63        | Caucasian | Benign (needle biopsy) | No | None |
| 7       | 58        | Hispanic  | ER-PR-Her2−–Stage I | No | Lumpectomy; radiation; chemotherapy (Paclitaxel and Carboplatin) |
| 8       | 54        | Caucasian | ER-PR-Her2–Stage II | No | Surgery (mastectomy), Chemotherapy |
| 9       | 36        | Black     | ER+PR+Her2+ | No | Post-surgery, radiation, Herceptin; Chemotherapy (AC − T); On Tamoxifen |
| 10      | 53        | Hispanic  | Stage II ER+PR+Her2+ | No | Lumpectomy; 4 cycles Paclitaxel; One year Herceptin; 4 yrs Tamoxifen |
| 11      | 56        | Hispanic  | Stage III ER+PR-Her2+ | No | Mastectomy; Radiation; Chemotherapy (Docetaxel, Paclitaxel, Herceptin) |
| 12      | 56        | Hispanic  | Stage I ER+PR-Her2− | No | Mastectomy; Taxol, No radiation, On Tamoxifen |
| 13      | 66        | Black     | Stage IV ER+PR+Her2+ | Yes | Taxotere; Herceptin, Hormone (Faslodex) Post-chemotherapy − bone pain |
| 14      | 64        | Hispanic  | Stage I ER+PR+Her2+ | No | ECOG 5103 Trial (Bevacizumab), Herceptin, Hormone (Arimidex) |
| 15      | 59        | Black     | ER+PR+Her2−–Stage II | No | Lumpectomy, radiation, chemotherapy (AC − T); Hormone (Tamoxifen) |
| 16      | 50        | Caucasian | Stage III ER+PR+Her2+ | No | Post-treatment (Chemotherapy and surgery) |
| 17      | 48        | Hispanic  | Stage III ER-Her2− | No | Post-treatment (2015); follow-up |
| 18      | 45        | Black     | Stage II (2006); Relapse (2015) ER-PR- Her2− | Chest wall (2015) | Mastectomy at initial diagnosis (2006); Radiation in 2015 |
| 19      | 48        | Hispanic  | Stage IIA ER+PR+Her2+ | No | Mastectomy; Completed Chemotherapy (Adriamycin, Cytokan, Paclitaxel); Hormone (Tamoxifen) |
| 20      | 85        | Black     | Stage IV ER+PR+Her2− | Yes | Hormone (Arimidex) |

Table 1. Patient demographics. AC − T = Adriamycin, cyclophosphamide, Paclitaxel. Pre- indicates that the blood was analyzed before chemotherapy. Post- refers to blood sampling after chemotherapy or after surgery. In cases where ‘Relapse’ is not included in Column 4, this indicates that the tumor was primary and not from relapse.
cell lines and primary tumor cells for functional studies. A prospective study is needed to validate the prognostic significance of developmental markers identified here, and use a developmental hierarchy-based patient selection in enabling precise treatment approaches.

Materials and Methods

Reagents. DMEM, RPMI 1640, α-MEM, recombinant human insulin were purchased from Life Technology (Grand Island, NY), fetal calf sera (premium) from Hyclone Laboratories (Logan, UT), restore western blot strips - ping buffer, cytoplasmic extraction kit and SuperSignal West Femto Maximum Sensitivity Substrate reagent from Thermo Scientific (Rockford IL), effectene transfection reagent from QIAGEN (Valencia, CA).

Antibodies. Rabbit anti-human TMEM98 (Catalog #NBP1-84154), FAT4 (Catalog #NBP1-78381) and GPR64 (Catalog #NBP1-84906) were purchased from Novus (Littleton, CO), RAP1A, APC-mouse anti-human CD44 from BD Pharmingen (San Jose, CA), PE-mouse anti-human CD24 and PE-murine IgG isotype from Biolegend (San Diego, CA), PerCP-Cy5.5- anti-rabbit IgG from Santa Cruz Biotechnology (Dallas, TX), PE-anti- human pan-cytokeratin from Abcam (Cambridge, MA) and APC-mouse IgG isotype control from (BD Biosciences). Mouse anti-fibronectin (FN1) was prepared as ascites from a hybridoma cell line that was purchased from ATCC.

Cells. MDA-MB-231 (highly invasive, basal-like) and T47D (low-invasive, luminal) BCCs and K562 cells were purchased from American Type Culture Collection (ATCC). The cells were cultured as per ATCC instructions. BCCs, stably transfected with Oct4-GFP, were previously described. Briefly, the cells were transfected with pEFGP1-Oct3/4 and then selected with neomycin. Similarly, stable transfectants of BCCs with pDsRed2-1-Oct3/4-SB were selected with neomycin.

Ethical statement. The use of human blood was approved by the Institutional Review Board (IRB) of Rutgers, Newark Campus. All subjects signed the informed consent forms. Furthermore, the studies were conducted as outlined in the IRB protocol.

Human subjects. Blood (2–5 mL) was taken from left over samples after diagnostic tests from BC patients. The demographics of the patients and their treatment at the time of blood draw are outlined in Table 1.

Vectors. pEFGP1-Oct3/4, which contained the Oct4A promoter, was generously provided by Dr. Wei Cui (Imperial College London, UK). The insert Oct4 insert from pEFGP1-Oct3/4 was removed using the restriction enzymes, HindIII and AgeI. Since the insert and the vector were similar size, a further digestion was performed with NotI to cut the vector backbone from pEGFP. This separated the backbone vector and the Oct4 insert. The

| Patient | Treatment Pre Ongoing Post | Date Tested | Circulating BBCs | Outcome (3/2017) |
|---------|----------------------------|-------------|------------------|-----------------|
| 1       | +                          | 3/10/15     | Early Progenitor | Metastasis      |
| 2       | +                          | 3/10/15     | Late Progenitor  | Passed          |
| 3       | +                          | 3/12/15     | Early Progenitor | Passed          |
| 4       | +                          | 3/18/15     | Early Progenitor | No clinical active disease |
| 5A      | +                          | 4/29/15     | CSC+++          | Not applicable  |
| 5B      | +                          | 7/8/15      | Early Progenitor | Bone metastasis |
| 6       | None                       | 5/5/15      | ND              | No clinical active disease |
| 7       | +                          | 10/12/16    | ND              | No clinical active disease |
| 8       | +                          | 10/12/16    | ND              | No clinical active disease |
| 9       | +                          | 8/11/16     | Late Progenitors| No clinical active disease |
| 10      | +                          | 8/11/16     | Late Progenitors| No clinical active disease |
| 11      | +                          | 8/15/16     | ND              | No clinical active disease |
| 12      | +                          | 8/16/16     | ND              | No clinical active disease |
| 13      | +                          | 8/17/16     | CSC++           | Bone metastasis |
| 14      | +                          | 8/18/16     | ND              |                  |
| 15      | +                          | 10/12/16    | Early Progenitor| No sample post-treatment |
| 16      | +                          | 5/3/16      | ND              | No clinical active disease |
| 17      | +                          | 8/30/16     | ND              | No clinical active disease |
| 18      | +                          | 9/6/16      | Progenitor      | No clinical active disease |
| 19      | +                          | 9/7/16      | Mixed Progenitors(Early-Late) | No clinical active disease |
| 20      | +                          | 9/15/16     | ND              | No clinical active disease |

Table 2. Phenotype of circulating BCCs in patients. The patient demographics shown in Table 1 depicts the stratification of breast cancer cells detected in the peripheral blood during and after treatment. ND: No breast cancer detected; CSC: Cancer stem cells, based on the hierarchy shown in Fig. 5.
Induced Oct4 expression. Induction of Oct4 was performed as described. BIX-01924 was added at varying concentrations (0 nM, 10 nM, 100 nm, 1 μM, 3 μM, and 10 μM) to 6-well tissue culture plates (Falcon, Pittsburg, PA). Induced Oct4 was indicated by the expression of dsRed, after 24 h, by flow cytometry.

Sorting of BCC subsets. BCCs were stably transfected with pEGFP1-Oct3/4 and then profiled based on GFP intensity. The relative intensity formed the basis for sorting with the fluorescent-activated cell sorting (FACS) with a FACSAria II cell sorter (BD Biosciences). The sorting was performed as previously described, using the top and lower 5% GFP cells and the population in the middle of the two extreme subsets (3). The sorted cells were designated Oct4hi, Oct4med and Oct4lo. Cells were analyzed using the FACSDiva (BD Biosciences). A representative image of the sorted cells are shown in Fig. S6.

Western Blot. Whole cell extracts were isolated with M-PER. The extracts were assayed for total protein using Pierce BCA Protein Assay Kit (Thermo Scientific). Extracts (10 μg) were electrophoresed at 150 volts on gradient (4–20%) SDS PAGE pre-cast gels (Bio-Rad, Hercules, CA). The proteins were transferred onto PVDF membranes (Perkin Elmer, Waltham, MA) for 1 h with 100 volts at 4 °C. The membranes were incubated overnight with primary antibodies in 5% milk-PBS solution at 4 °C at 1/1000 final dilution. The same membranes were stripped with Restore Western blot Stripping Buffer and then reprobed with the different antibodies. The band densities were normalized to those of β-actin.

After incubation with the antibodies the membranes were washed four times with 1 × PBS containing 0.1% TWEEN. The membranes were incubated with HRP-anti-murine IgG (1/2000) or HRP-anti-rabbit IgG (1/2000), depending on the primary antibody for 2 h at 4 °C. The normalization antibodies for Histone H3 and β-actin were added at final dilution of 1/1000 and 1/4000, respectively. After this, the membranes were subjected to additional washes three times, followed by detection with Western Lightning Chemiluminescent Reagent. The molecular weights of the bands were determined by comparing with Kaleidoscope Pre-stained standards (BioRad). Band densities were normalized to β-actin with the Un-Scan-It software (Silk Scientific Inc, Orem, Utah).

Flow cytometry. BCCs (5 × 10^6) (MDA-MB-231 and T47D) with stable transfection of Oct4-GFP cells were resuspended in 2 ml of 1 × phosphate buffered saline (PBS, pH 7.4) and then fixed with 1 ml of 3.7% formaldehyde (diluted in PBS). Cells were incubated for 15 min at room temperature and then permeabilized for 30 min with 1 ml of 0.2% Triton-X 100 (diluted in PBS) at room temperature. Cells were washed twice with 2 ml of 0.5% Bovine Serum Albumin in PBS (incubation buffer) and then resuspended at 1:1 ratio of methanol-PBS. After 10 min incubation, cells were washed twice with incubation buffer. Cells were triple labeled for CD24 (1/30) and CD44 (1/100) and either for TMEM98 (1/100 final dilution), or FAT4 (1/200 final dilution), or GPR64 (1/200 final dilution), at 10^6/150 μl of incubation buffer for 60 min at RT. After washing cells twice with incubation buffer, cells were stained with secondary antibodies at 1/500 final dilution for 15 min incubation, cells were washed twice with incubation buffer. Cells were triple labeled for CD24 (1/30) and CD44 (1/100) and either for TMEM98 (1/100 final dilution), or FAT4 (1/200 final dilution), or GPR64 (1/200 final dilution), and 10^6/150 μl of incubation buffer for 60 min at RT. After washing cells twice with incubation buffer, cells were stained with secondary antibodies at 1/500 final dilution for 30 min at RT in the dark. This was followed by two washes with incubation buffer. Cells were resuspended in 1% formaldehyde and immediately analyzed on the FACSCalibur (Becton and Dickson).

Mononuclear cells from the blood of patients were isolated by Ficoll Hypaque Density Gradient. The cells were labeled for CD45, CD24 and CD44. Cells were resuspended in 2 ml of 1 × phosphate buffered saline (PBS, pH 7.4) and then fixed with 1 ml of 3.7% formaldehyde (diluted in PBS). Cells were incubated for 15 min at room temperature and then permeabilized for 30 min with 1 ml of 0.2% Triton-X 100 (diluted in PBS) at room temperature. Cells were washed twice with 2 ml of 0.5% Bovine Serum Albumin in PBS (incubation buffer) and then resuspended at 1:1 ratio of methanol-PBS. After 10 min incubation, cells were washed twice with incubation buffer. Cells were labeled for CD24 (1/30) and CD44 (1/100) and either for TMEM98 (1/100 final dilution), or FAT4 (1/200 final dilution), or GPR64 (1/200 final dilution). Data were analyzed with BD CellQuest (BD Biosciences). The geometric (Geo) mean, shown in Fig. 4, was calculated by subtracting the mean fluorescence intensity (MFI) of isotype control from the experimental MFI. The relative amount of circulating tumor cells (CTCs) were determined by the relative MFI of specific subsets based on the hierarchy shown in Fig. 5.

Aldefluor Assay. Aldefluor assay was performed with BCCs, untransfected or stably transfected with Oct4-dsRed cells using a kit from Stem Cell Technologies (Vancouver, Canada). The assay was performed according to the manufacturer’s instructions. The K562 cell line served as a positive control. The aldefluor reagent was added to the cells, incubated for 1 h, and then analyzed by flow cytometry. The relative intensity formed the basis for sorting with the fluorescent-activated cell sorting (FACS) with a FACSAria II cell sorter (BD Biosciences). The sorting was performed as previously described, using the top and lower 5% GFP cells and the population in the middle of the two extreme subsets (3). The sorted cells were designated Oct4hi, Oct4med and Oct4lo. The assay was performed using the FACSDiva (BD Biosciences). A representative image of the sorted cells are shown in Fig. S6.

Telomere Length Assay. Telomere length was assayed with the TeloTAGGG Telomere Length Assay from Roche Diagnostics (Indianapolis, IN) according to the manufacturer’s protocol. The cells were sorted as described above and genomic DNA isolated with the QIAamp DNA Mini Kit from Qiagen (Valencia, CA).

Real time PCR. RNA extraction was performed per manufacturer’s protocols with the RNeasy Mini Kit (Qiagen, Valencia, CA). Quality and concentration of RNA were determined with the Nanodrop ND-1000 spectrophotometer. The High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Grand Island, NY) was used to convert RNA to cDNA. Real-time PCR was performed with 10 ng of cDNA using either Taqman Universal PCR Master Mix II or Power SYBR® Green PCR Master Mix (Life Technologies, Grand Island, NY). TaqMan primers were purchased for RAP1A and PPIB from Life Technologies, other primer sequences are in Supplemental Table 2.
Affymetrix Array. MDA-MB-231-pEGFP1-Oct3/4 cells were sorted into three conditions as stated above. In four different experiments, total RNA was isolated from the sorted cells with Qiagen RNeasy Mini Kit (Qiagen). The RNA quality was assessed on the Agilent Bioanalyzer 2100. Total RNA (100 ng) was converted to cDNA, cRNA, and fragmented according to the manufacturer's protocol with the assistance of the Biomek FX® Target Prep Express with standard scripts for 3'IVT Express for Gene Expression. Fragmented samples were hybridized to GeneChip Human Genome U133 Plus 2.0 Arrays and then washed and stained following the manufacturer's protocols. The hybridized GeneChip Arrays were scanned with a GeneChip Scanner 3000 7 G (Agilent/Affymetrix) and the data saved in .cel files.

Data Analyses. A CONSORT chart is outlined to show how the samples were used in the Affymetrix analyses (Fig. S1). Three BCC subsets were selected based on GFP expression, which we correlated with Oct4A expression, based on previous studies. The sorted cells were assigned Oct4hi, Oct4med, Oct4lo. Oct4hi and Oct4lo were tested in quadruplicate, except for Oct4med, which was tested in duplicate. Genes < 1.2 fold among the different subsets were filtered and the resulting genes were subjected to further analyses with multiple programs. This allowed us to reduce inherent bias of the individual program: Partek® Genomics Suite software, version 6.11.0801 (Partek Inc., St. Louis, MO), Gene Spring GX 10.2 (Agilent Technologies, Santa Clara, CA); QIAGEN's Ingenuity® iReport (QIAGEN Redwood City, CA) and BRB-Array Tool, version 4.4.0 developed by Dr. Richard Simon and BRB-Array Tools Development Team. Oct4hi, Oct4low and Oct4med samples were considered as replicates if they were under the same condition. Average intensity values across each replicate were taken into consideration for analysis. Further statistical analysis was done in each program and noted in the figures.

Background corrected hybridization intensities were imported into BRB-Array Tools Version 4.4.0 log2-transformed and robust multi-array average (RMA) normalized (36). Features not significantly above background intensity in 50% or more of the samples, and features not changing at least 1.2-fold in at least 20% of the samples were filtered out. This yielded 25,750 features that were used in subsequent analyses.

BRB class comparison was conducted to identify genes that were differentially expressed. Two-sample t-test or F-test (more than 2 classes) based p value was calculated for each significant gene with random variance model. Genes with p-values of < 0.001 were considered significant. The false discovery rate was also estimated for each gene to control false positive, as described (46). Multidimensional scaling was performed in BRB-ArrayTools to represent high-dimensional data (e.g., a selected gene list with relative expression) graphically in low dimensions. The Euclidian distance metric was used to compute a distance matrix and the principal components of the gene expression signature. Each sample was then represented by a single point and the distance between two points indicated the overall similarity of those two samples. The first three principal components of gene expression were used as axes to generate a plot. Data was also visualized using hierarchical clustering in BRB-Array Tools. The Euclidian distance metric and average linkage was used to cluster genes and generate a heat map.

Pathway and networking by Ingenuity Pathway Analysis (IPA). The significantly differentially expressed genes (p < 0.001, FDR < 0.6%) were imported into Ingenuity Systems (http://www.ingenuity.com/). The IPA knowledge base filter mapped 2705 transcripts to known genes in IPA. We next performed IPA core-analysis in the context of pathways and networks, biological function and/or diseases. The right-tailed Fisher's exact test was applied to calculate the p value ascertaining the probability that each biological function and/or disease. IPA core analysis identified 1721 genes as the highest significant functional category associated with cancer (p < 2.10E-15) and 344 genes relevant to BC (p < 3.10E-13). Of the 344 genes over-represented for BC, 99 of these genes have relative fold change > 1.5. We used pathway analysis to determine whether Oct4hi expression was connected to genes associated with BC at the molecular network level based on connectivity information in the IPA Knowledge Base. We added molecules suggested by the IPA “pathway explorer” in order to connect molecules of interest. Priority was given to those molecules with a high degree of connectivity within the pathway rather than molecules with many connections to molecules not on the pathway.

Data availability. The dataset generated with the Affymetrix gene arrays are available through the GEO database using accession number GSE 86861.

References
1. Riethdorf, S., Wikman, H. & Pantel, K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int. J Cancer 123, 1991–2006 (2008).
2. Braun, S. & Pantel, K. Micrometastatic bone marrow involvement: detection and prognostic significance. Med Oncol 16, 154–165 (1999).
3. Patel, S. A. et al. Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Sci. Rep 2, 906 (2012).
4. Rao, G. et al. Facilitating Role of Preprotachykinin-I Gene in the Integration of Breast Cancer Cells within the Stromal Compartment of the Bone Marrow: A Model of Early Cancer Progression. Cancer Res 64, 2874–2881 (2004).
5. Habeck, M. Bone-marrow analysis predicts breast-cancer recurrence. Mol Med Today 6, 256–257 (2000).
6. Mansi, J. L. et al. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 7, 445–449 (1989).
7. Naume, B. et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 1, 160–171 (2007).
8. Weigelt, B., Peterse, J. L. & van't Veer, L. J. Breast cancer metastasis: markers and models. Nat Rev Cancer 5, 591–602 (2005).
9. Mani, R. M. H. Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State. Cancer Res 77, 2564–2659 (2017).
10. Braun, S. et al. Comparative Analysis of Micrometastasis to the Bone Marrow and Lymph Nodes of Node-Negative Breast Cancer Patients Receiving No Adjuvant Therapy. J Clin Oncol 19, 1468–1475 (2001).
11. Talnadge, J. E. Clonal Selection of a Tumor. Cancer Res 67, 11471–11475 (2007).
12. Fuller, I. J. Tumor Heterogeneity and the Biology of Cancer Invasion and Metastasis. Cancer Res 38, 2651–2660 (1978).
13. Fuller, I. J. Commentary on “Tumor Heterogeneity and the Biology of Cancer Invasion and Metastasis”. Cancer Res 76, 3441–3442 (2016).
14. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *New Engl J Med* **315**, 1650–1659 (1986).
15. Braun, S. *et al.* Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients. *Journal of Clin Oncol* **18**, 80–86 (2000).
16. Anthony, B. A. & Link, D. C. Regulation of hematopoietic stem cells by bone marrow stromal cells. *Trends Immunol* **35**, 32–37 (2014).
17. Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. *Nat Rev Cancer* **7**, 834–846 (2007).
18. Braun, S. *et al.* A pooled analysis of bone marrow micrometastasis in breast cancer. *New Engl J Med* **353**, 793–802 (2005).
19. Fidler, I. J. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2′-deoxyuridine. *J Natl Cancer Inst* **45**, 773–782 (1970).
20. Gossa, P. E. & Chambers, A. F. Does tumour dormancy offer a therapeutic target? *Nat Rev Cancer* **10**, 871–877 (2010).
21. Li, Y. & Laterra, J. Cancer Stem Cells: Distinct Entities or Dynamically Regulated Phenotypes? *Cancer Res* **72**, 576–580 (2012).
22. Bianco, P. Stem cells and bone: A historical perspective. *Bone* **70**, 2–9 (2015).
23. Lim, P. K. *et al.* Gap Junction-Mediated Import of MicroRNA from Bone Marrow Stromal Cells Can Elicit Cell Cycle Quiescence in Breast Cancer Cells. *Cancer Res* **71**, 1550–1560 (2011).
24. Patel, S. A. *et al.* Mesenchymal Stem Cells Protect Breast Cancer Cells through Regulatory T Cells: Role of Mesenchymal Stem Cell-Derived TGF-beta. *J Immunol* **184**, 5885–5894 (2010).
25. Moharita, A. L. *et al.* SDF-1a regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis. *Blood* **108**, 3245–3252 (2006).
26. Patel, S. A. *et al.* T<sub>α</sub>β1 polarization by distinct subsets of breast cancer cells is dictated by the interaction with mesenchymal stem cells. *J Cancer Stem Cell* **2**, e1003 (2014).
27. Greco, S. *et al.* AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells. *Am J Cancer Res* **1**, 701–715 (2011).
28. Bliss, S. A. *et al.* Mesenchymal stem cell-derived exosomes stimulates cycling quiescence and early breast cancer dormancy in bone marrow. *Cancer Res* **76**, 5832–5844, https://doi.org/10.1158/0008-5472.CAN-16-1092 (2016).
29. Price, T. T. *et al.* Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. *Sci Transl Med* **8**, 340ra273 (2016).
30. Fenrette, P. S., Pinho, S., Lucas, D. & Scheiermann, C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. *Ann Rev Immunol* **31**, 285–316 (2013).
31. Richter, R., Forssmann, W. & Henschler, R. Current Developments in Mobilization of Hematopoietic Stem and Progenitor Cells and Their Interaction with Niches in Bone Marrow. *Transfusion Med Hemother* **44**, 151–164 (2017).
32. Braña, I. *et al.* A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. *Br J Cancer* **111**, 1932–1944 (2014).
33. De Jesus-Acosta, A. *et al.* A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. *Invest New Drugs* **32**, 739–745 (2014).
34. Stroebel, J. R. *et al.* A phase II study of RO4929097 in metastatic colorectal cancer. *Eur J Cancer* **48**, 987–1003 (2012).
35. Tajima, S. & Koda, K. Dedifferentiation-like progression of breast carcinoma: report of a case showing transition from luminal-type carcinoma to triple-negative carcinoma with myoepithelial features. *Int J Clin Exp Pathol.* **8**, 2117–2122 (2015).
36. Palen, K. *et al.* E-cadherin re-expression shows Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. *Sci Transl Med* **8**, 340ra273 (2016).
37. Shi, G. & Jin, Y. Role of Oct<sub>4</sub> in maintaining and regaining stem cell pluripotency. *Stem Cell Res Ther* **1**, 39 (2010).
38. Rivera, T., Haggblom, C., Cosconati, S. & Karlsseder, J. A balance between elongation and trimming regulates telomere stability in stem cells. *Nat Struct Mol Biol* **24**, 30–39 (2017).
39. Rafael, D. *et al.* EMT Blockade Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation. *Curr Gene Ther* **15**, 300–312 (2015).
40. Jung, H. Y. & Yang, J. Unraveling the TWIST between EMT and Cancer Stemness. *Cell Stem Cell* **16**, 1–2 (2015).
41. Deng, Z., Wu, Y., Ma, W., Zhang, S. & Zhang, Y. Q. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. *BMC Immunol* **16**, 1 (2015).
42. Condiotti, R., Guo, W. & Ben-Porath, I. Evolving views of breast cancer stem cells and their differentiation States. *Crit Rev Oncog* **19**, 337–348 (2014).
43. Benjamin, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J Royal Stat Soc* **57**, 289–300 (1995).

**Acknowledgements**

The work was supported by an award given by the Department of Defense, W81XWH-11-1-0276. This work was supported by a grant from the Department of Defense.

**Author Contributions**

Conception and Design: Sarah A. Bliss, Sunirmal Paul, Piotr W. Pobiarzyn, Seda Ayer, Pranela Rameshwar. Development of Methods: Sarah A. Bliss, Sunirmal Paul, Piotr W. Pobiarzyn, Seda Ayer, Saumya Pant, Holly Hilton, Neha Sharma, Daniel J. Engelberth, Steven J. Greco, Garima Sinha. Array Analyses: Sarah A. Bliss, Sunirmal Paul, Magdalena J, Kucia, Sham S. Kakar, Mariusz Z. Ratajczak, Neha Sharma. Collecting Data/Analyzing Patient samples: Maria F. Cunha, Margarete Bryan, Piotr W. Pobiarzyn, Garima Sinha. Writing and review of manuscript: Sarah A. Bliss, Sunirmal Paul, Magdalena J, Kucia, Sham S. Kakar, Mariusz Z. Ratajczak, Piotr W. Pobiarzyn, Maria F. Cunha, Margarete Bryan, Holly Hilton, Garima Sinha. Study supervision: Pranela Rameshwar.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-017-18834-5.

**Competing Interests:** The authors declare that they have no competing interests.
